Magnetic Cell Delivery
Regenerative medicine using cell therapies to replace or enhance damaged tissue is often limited by the ability to localize these cells to the target tissue. Once delivered, these cells then need to remain at that site to facilitate integration into the host tissue.
Using a proprietary Magnetic Cell Delivery nanoparticle platform, Emmecell solves the challenges of delivery, retention, and integration of cell therapies by leveraging magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue.
Emmecell has a broad IP portfolio and is focusing its initial efforts on ophthalmic indications.
Add Your Title
This is a great place to add a tagline.
Tell customers more about you. Add a few words and a stunning pic to grab their attention and get them to click.
This space is ideal for writing a detailed description of your business and the types of services that you provide. Talk about your team and your areas of expertise.
Treatment for Corneal Edema
A cell injection to replace corneal surgery
When corneal endothelial cells—which line the inner-most layer of the cornea—decrease in number, whether from the trauma of cataract surgery or from disease or dystrophy, the cornea swells with fluid (edema), and loses its optical clarity. Patients with corneal edema suffer from vision loss and pain.
Currently, there are no non-surgical procedures approved for the treatment of advanced corneal edema. The only options for these patients are corneal transplantation surgery or endothelial keratoplasty, which are technically demanding procedures with many limitations. Corneal edema is the most common indication for corneal transplantation.
Emmecell’s exclusive Magnetic Cell Delivery addresses the limitations of the current surgical options with a safe, effective, non-surgical approach to transplant its proprietary corneal endothelial cells in the eye. With the availability of an effective and safe therapeutic option for corneal edema, patients with clinically significant disease, whether mild or advanced, will now have an accessible and effective treatment.
Xia X, Atkins M, Dalal R, Kuzmenko O, Chang KC, Sun CB, Benatti CA, Rak DJ, Nahmou M, Kunzevitzky NJ, Goldberg JL. Magnetic Human Corneal Endothelial Cell Transplant: Delivery, Retention, and Short-Term Efficacy. Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2438-2448. doi: 10.1167/iovs.18-26001. PMID: 31158276; PMCID: PMC6546151.
Bartakova A, Kuzmenko O, Alvarez-Delfin K, Kunzevitzky NJ, Goldberg JL. A Cell Culture Approach to Optimized Human Corneal Endothelial Cell Function. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1617-1629. doi: 10.1167/iovs.17-23637. PMID: 29625488; PMCID: PMC5869002.
Moysidis SN, Alvarez-Delfin K, Peschansky VJ, Salero E, Weisman AD, Bartakova A, Raffa GA, Merkhofer RM Jr, Kador KE, Kunzevitzky NJ, Goldberg JL. Magnetic field-guided cell delivery with nanoparticle-loaded human corneal endothelial cells. Nanomedicine. 2015 Apr;11(3):499-509. doi: 10.1016/j.nano.2014.12.002. Epub 2015 Jan 14. PMID: 25596075; PMCID: PMC4691344.
Bartakova A, Kunzevitzky NJ, Goldberg JL. Regenerative Cell Therapy for Corneal Endothelium. Curr Ophthalmol Rep. 2014 Sep 1;2(3):81-90. doi: 10.1007/s40135-014-0043-7. PMID: 25328857; PMCID: PMC4196268.